333 results about "Oxaliplatin" patented technology

The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula: (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group; W represents a single bond or -CH=CH-; X represents -NH- etc.; and Y represents a carbon atom or a nitrogen atom; and Z represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil; (4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin; (7) taxol; (8) carboplatin; (9) oxaliplatin; (10) capecitabine; and (11) a salt of the above-mentioned (1) to (10).

The invention provides a biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle and a preparation method thereof, which relate to the field of novel chemical synthesis medicaments and preparations thereof and are used for solving the problem that a high-polymer-platinum (IV) bonded medicament does not have optical activity in the prior art. In an anticancer medicament, ethylene glycol-b-polyester-b-polylysine serving as a biodegradable triblock copolymer or polyethylene glycol-b-poly(ester-co-carbonic ester) serving as a diblock copolymer is taken as a carrier polymer, and Pt (IV) is a photoactive tetravalent platinum composition coordinated with dihydroxyl in the axial direction. The invention further provides a preparation method of the biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle. The anticancer medicament prepared with the method has remarkable optical activity; under the irradiation of UV (Ultraviolet) of 365 nanometers, Pt (IV) is reduced into Pt (II); a cis-platinum or oxaliplatin antitumor active part is contained; and the mass content of platinum can be up to 10-20 percent.

The invention relates to oxaliplatin freeze-dried injection, which is characterized in that the invention is prepared by the method that aqueous solution is freeze-dried. The aqueous solution contains oxaliplatin, mannitol and citrate, wherein, the concentration of the oxaliplatin in the aqueous solution is 2.5 to 6.25 mg / ml; the concentration of the mannitol in the aqueous solution is 25 to 200 mg / ml; and the concentration of the citrate in the aqueous solution is 2 to 20 mg / ml. And sodium citrate can also be added into the aqueous solution so as to adjust the pH of the aqueous solution. The preparation processes are as following: the oxaliplatin is placed inside the container, 80 percent amount of water for injection is added, and then the water for injection is mixed so that the oxaliplatin can be dissolved and mixed evenly in the water for injection; after that, the mannitol and the citrate are added into the water for injection, and then the water for injection is mixed so that the mannitol and the citrate can be dissolved and mixed evenly in the water for injection; the content of the intermediate is measured; if the content of the intermediate is qualified, the volume of the water for injection is fixed to full amount; in the aseptic condition, the water for injection is filtered until to be clear by a microporous membrane of 0.22 microns; the filtered solution is filled into an aseptic silin bottle; part of the aseptic silin bottle is plugged with a butyl rubber closure; and then the aseptic silin bottle is filled in the tray to be sent into the freeze dryer to be freeze-dried; the mouth of the aseptic silin bottle is rolled; the quality of the filtered solution is inspected; and the aseptic silin bottle is packaged.

Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and / or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and / or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and / or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and / or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.

Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as oxaliplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, colorectal cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

The invention relates to an oxaliplatin crystal compound. The oxaliplatin crystal compound is measured by using a powder X-ray diffraction measurement method. Characteristic diffraction peaks are shown at positions of 6.5 degrees, 9.8 degrees, 11.2 degrees, 13.7 degrees, 17.5 degrees, 18.5 degrees, 19.7 degrees, 22.4 degrees, 23.2 degrees, 26.8 degrees, 27.1 degrees, 33.8 degrees, 35.2 degrees, 36.9 degrees and 43.8 degrees in an X-ray powder diffraction pattern shown by a diffraction angle of 2theta+ / -0.2 degree. The oxaliplatin crystal compound is good in dissolubility.

The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.

The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.

The invention discloses an enhancement tumor cell medicament screening method and its application mainly for effectively overcoming the multidrug resistance to improve the anti-cancer drug treatment effect in a tumor chemotherapy process. The invention screens an inhibitor which can effectively inhibiting the induction action through luciferase activity detection by using an Nrf2 as a cell drug screen platform of a molecular target and a tBHQ as an Nrf2 inducer, and the inhibitor is a medicament of the enhancement tumor cell. The medicament obtained by the screen is a small molecular compound ZDAK02 (coralyne sulfoacetate coralyne thioacetate). The combined use of the medicament of the invention with the anti-cancer drug Chlorambucil or anti-cancer drug oxaliplatin can enhance the toxicity of the anti-cancer drug to the cancer cells and be helpful for easing even reversing the multidrug resistance to the anti-cancer drugs.

The invention relates the method of refining osali platinum, comprising the following steps: dissolving the osali platinum into water at 40-100Deg.C, the rate of osali platinum and water being 5-100, adding C1-3 alkylol groups, cooling, extracting crystal, filtering, drying, and getting elaboration product, osali platinum The invention has the advantages of light osali platinum oxalic acid content and high productivity.